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Abstract
Background: Patients with chronic kidney disease have worse outcomes after stroke. However, the burden of acute
kidney injury after stroke has not been extensively investigated.
Methods: We used MEDLINE and Embase to conduct a systematic review and meta-analysis of published studies that
provided data on the risk of AKI and outcomes in adults after ischemic and hemorrhagic stroke. Pooled incidence was
examined using the Stuart-Ord method in a DerSimonian-Laird model. Pooled Odds Ratios and 95% confidence
intervals were calculated for outcomes using a random effects model. This review was registered with PROSPERO
(CRD42017064588).
Results: Eight studies were included, five from the United States, representing 99.9% of included patients. Three studies
used established acute kidney injury criteria based on creatinine values to define acute kidney injury and five used
International Classification of Diseases coding definitions. Overall pooled incidence was 9.61% (95% confidence interval 8.
33–10.98). Incidence for studies using creatinine definitions was 19.51% (95% confidence interval 12.75–27.32%) and for
studies using coding definitions 4.63% (95% confidence interval 3.65–5.72%). Heterogeneity was high throughout.
Mortality in stroke patients who sustained acute kidney injury was increased (Odds Ratio 2.45; 95% confidence interval 1.
47–4.10). Three studies reported risk factors for acute kidney injury. There was sparse information on other outcomes.
Conclusions: Mortality in stroke patients who develop acute kidney injury is significantly increased. However the reported
incidence of AKI after stroke varies widely and is underestimated using coding definitions. Larger international studies are
required to identify potentially preventable factors to reduce acute kidney injury after stroke and improve outcomes.
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Background
Stroke is the leading cause of neurological disability world-
wide with huge social and economic impact [1]. In 2015
there were 6.24 million deaths caused by stroke [2]. Chronic
kidney disease (CKD) is associated with an increased risk of
stroke [3]. Some of this relates to shared traditional risk fac-
tors, for example hypertension, hypercholesterolemia, dia-
betes mellitus and cigarette smoking [4]. However CKD itself
has also been recognized as a risk factor for stroke [5, 6]. In a
recent systematic review and meta-analysis comprising 83
studies and 30,392 strokes, Masson et al. demonstrated that
stroke risk increased by 7% for every 10mls/min/1.73m2 de-
cline in glomerular filtration rate (GFR) [7].
Acute kidney injury (AKI) is a clinical syndrome defined as
an abrupt decrease in kidney function resulting in disturb-
ance of fluid, electrolyte and acid-base homeostasis [8]. AKI
is a spectrum, ranging from mild, asymptomatic injury to se-
vere injury requiring renal replacement therapy (RRT) [8, 9].
Over the last decade, with the development and wide adop-
tion of international classification systems [8–10], there has
been an increasing amount of research into the incidence of
AKI and its influence on adverse outcomes in both high and
low income countries [11–14].
After a stroke, neurological deficit leading to dysphagia
and physical disability, physiological effects including
changes in blood pressure and cerebral salt wasting, as well
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as investigations and treatments, can all potentially contrib-
ute to the development of AKI. Furthermore, older, comor-
bid patients are at greatest risk of AKI [14]. Strategies to
prevent AKI in stroke patients could therefore be of great
importance. Although the association between CKD and
stroke outcomes has been the subject of several systematic
reviews and meta-analyses [7, 15], the relationship between
AKI and stroke is much less clear. We therefore analyzed
the reported rates of AKI incidence after a stroke and the
associations between AKI and outcomes after a stroke.
Methods
Our systematic review was registered with PROSPERO
(CRD42017064588) and we adhered to the PRISMA
reporting statement [16]. A literature search of MEDLINE
was performed from 1946 through to 30 June 2017 using
relevant text words and medical subject headings acute
kidney injury, acute kidney failure, acute renal failure,
acute renal insufficiency, combined with stroke, cerebro-
vascular disorders and CVA or TIA. Embase was searched
from 1974 to 30 June 2017, using the same medical sub-
ject headings for AKI as for MEDLINE, combined with
cerebrovascular accident, cerebrovascular disease, cerebro-
vascular disorder, brain hemorrhage; brain infarction and
stroke (for a detailed search strategy see Additional file 1).
All searches were limited to human studies with no lan-
guage restrictions. Authors manually reviewed the reference
lists of retrieved articles for additional relevant studies.
Study selection
Study eligibility was determined using a standardized form
(Additional file 2). Two authors, JA and KN, independently
screened the list of studies generated by the search, with
disagreements resolved by a third author, CF. Titles and ab-
stracts of all studies were screened before obtaining full text
versions of relevant studies. To improve generalizability,
studies were included if they were a case control or cohort
(prospective or retrospective) study and had a sample size
greater than 500 adult subjects hospitalized with either an
acute ischemic or hemorrhagic stroke [17]. Included studies
had a clear statement regarding the definition of acute kid-
ney injury - creatinine values alone were not sufficient. Sub-
arachnoid hemorrhage was not included in this systematic
review in view of the different aetiopathophysiology.
Data collection and analysis
Data was collected using a standardized proforma
(Additional file 2) by JA and KN. The following study de-
tails were recorded: authors, year of publication, country of
publication, type of study, clinical setting, sample size, pa-
tient characteristics (age, sex, ethnicity, and comorbidities),
definition, type and severity of stroke and definition of AKI.
Clinical parameters on admission, including serum creatin-
ine and/or GFR, exposure to radiocontrast media, where
specified and number of patients who developed AKI were
recorded. Outcomes including mortality, disability, length
of stay, re-stroke or cardiac events were also recorded.
Study quality assessment was performed independently
by two authors, JA and CF using the Newcastle-Ottawa
scale [18]. A maximum of 9 points can be allocated to a
particular study based on quality of selection, comparabil-
ity and study outcome (including follow up). Scores were
defined as poor (0–3), fair (4–6) and good (7–9) [17].
Data synthesis, meta-analysis and statistical analysis were
performed using Review Manager v5.3.5 software (The
Cochrane Collaboration, UK) and StatsDirect v3.0 (StatsDirect
Limited, UK). Meta-analysis of proportions was carried out
using the Stuart-Ord (inverse double arcsine square root)
method in a DerSimonian-Laird (random effects) model. The
Odds Ratio (OR) with accompanying 95% confidence intervals
(95% CI) were used to report individual and summary effect
measures for dichotomous data. Chi squared tests for hetero-
geneity were performed to examine if the degrees of freedom
were greater than the Cochran Q statistic, with α of below
0.05 considered to be statistically significant. In addition, the I2
statistic was calculated to provide the estimated percentage of
heterogeneity observed. I2 values of 25%, 50% and 75% corres-
pond to low, medium and high levels of heterogeneity. Any
heterogeneity was further explored. A two-sided P value of <
0.05 was considered significant for all analyses.
Results
Study characteristics
A total of 6173 potentially relevant citations were identified
(Fig. 1), of which 816 were duplicates. A further 5309 articles
were excluded after review of title and abstract and an add-
itional 40 excluded after full text review. The characteristics
of the eight included studies are displayed in Table 1 [19–26]
with the study outcomes summarized in Table 2. All eight
studies were published in the English language between 2007
and 2015. Seven studies were considered to be of good quality
and one of fair quality. The eight studies provided data on
12,325,652 patients (range 897 to 7,068,334) from four coun-
tries (five from the US [20, 22–24, 26], and one each from
China [21], Greece [25] and Romania [19]). The US studies
overwhelmingly had the largest sample sizes, with a total of
12,319,724 patients representing 99.9% of all included pa-
tients. Three of the US studies used Nationwide Inpatient
Sample (NIS) data [23, 24, 26]. Although the same database
was used, one study included only patients with ischemic
stroke [23], one study included only patients with
hemorrhagic stroke [24] and a third included only patients
who sustained AKI requiring dialysis treatment (AKI-D) [26].
Therefore it was considered appropriate to include only the
first two in the meta-analysis [23, 24]. Five out of eight
studies used the International Classification of Diseases-9th
or 10th Edition (ICD-9/1CD-10) coding to define AKI [21–
24] and AKI-D [26]. Only one of the studies reported data
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on AKI-D in addition to overall AKI incidence [24]. Two
studies used the Acute Kidney Injury Network (AKIN) clas-
sification [20, 25] and one the Risk/ Injury/ Failure/ Loss/
End-stage (RIFLE) classification [19]. None used urine out-
put criteria. Although there are some differences in the
grading of AKI severity between these classifications, both
define the absolute incidence of AKI as an increase in
serum creatinine > 150%. Stroke was determined using ICD
coding in four studies [22–24, 26]. Three studies utilized
the World Health Organization (WHO) definition of stroke
[27] and extracted clinical data from medical records pro-
spectively [21, 25] or retrospectively [19]. Two studies [21,
25] further subclassified the etiology of ischemic stroke
using TOAST criteria [28]. One study utilized stroke regis-
try data as well as clinical records and ICD coding [20].
Five studies followed patients until discharge from hospital
[20, 22–24, 26], one for 30 days [19], one from hospitalization
up to one year [21] and one from 30 days up to 10 years [25]
(Table 2). Two studies excluded patients with known CKD
[23, 24] and two studies excluded patients with end-stage
renal disease (ESRD) [20, 26]. Ischemic and hemorrhagic
stroke patients were included in four of the studies [19, 20,
25, 26], ischemic stroke alone in three [21–23] and
hemorrhagic stroke alone in one study [24] (Table 2).
Pooled incidence of AKI after stroke
Nadkarni et al. reported the incidence of AKI-D only
[26]. This was 0.15% in hospitalizations with acute ische-
mic stroke and 0.35% in intracranial hemorrhage, with
an overall incidence of 0.5%. Saeed et al. reported an
overall incidence of AKI-D of 1.7% [24].
Using the remaining seven studies, the pooled proportion
of AKI as a percentage was 9.61% (95% CI 8.33–10.98)
(Fig. 2) with an I2 statistic of 99.8% indicating high hetero-
geneity. Excluding Lin et al. [21], which reported a much
lower incidence of AKI than any other study (0.82%), made
no difference to the heterogeneity (I2 99.9%).
The pooled incidence of AKI in the studies that utilized
ICD coding to define AKI [21–24] was 4.63% (95% CI 3.65–
5.72%). Heterogeneity was high (I2 99.9%). Excluding Lin et al.
[21], the pooled incidence of AKI increased to 6.46% (95% CI
5.18–7.86%) and heterogeneity remained high (I2 99.9%). Fur-
ther excluding the study of hemorrhagic stroke hospitaliza-
tions [24], the pooled incidence of AKI remained similar
(6.42%; 95% CI 4.07–9.27%) with high heterogeneity (I2
90.6%). In comparison, the pooled incidence in studies using
creatinine-based AKI definitions [19, 20, 25] was 19.51% (95%
CI 12.75–27.32%), again with high heterogeneity (I2 97.4%).
The pooled incidence of AKI in ischemic stroke [19–23,
25] was 9.62% (95% CI 4.20–16.96%; I2 statistic 99.5%). Ex-
cluding Lin et al. [21], AKI incidence increased to 12.45%
(95% CI 4.96–22.70%) and heterogeneity remained high (I2
99.5%). Using studies with a coding definition for AKI, the
pooled incidence was 4.05% (95% CI 1.06–8.86%; I2 statistic
99.1%). Pooled incidence of AKI in studies utilizing
creatinine-based definitions was 17.33% (95% CI 9.42–
27.05%) with high heterogeneity (I2 97.6%).
The pooled incidence of AKI in hemorrhagic stroke
[19, 20, 24, 25] was 19.17% (95% CI 7.75–34.15%).
Heterogeneity was high (I2 99.0%). Excluding Saeed et
al. 2015 [24], the only study in this group to use a
coding definition for AKI, the pooled incidence in-
creased to 24.50% (95% CI 18.03–31.61%). Heterogen-
eity decreased but remained high (I2 84.9%).
Risk factors for AKI after stroke
Factors associated with the development of AKI after multi-
variate analyses are shown in Table 2. Three studies ex-
plored risk factors for the development of AKI after stroke
[19, 20, 25]. Older age [19], worse renal function on admis-
sion [19, 20, 25], ischemic heart disease [19], heart failure
6173 citations identified 
through database search
MEDLINE: 975
Embase: 5198
816 duplicates removed
5357 study abstracts screened 
for relevance 
5309 excluded
48 full text articles assessed 
for eligibility 
40 full text articles excluded
10 studies small sample size 
(<500)
12 studies intervention with no 
control group and small 
sample size
3 studies intervention with no 
control group (adequate 
sample size)
5 studies overlapping patient 
population
3 studies CKD not AKI
3 studies no clear definition of 
AKI
1 study TIA
3 studies subarachnoid 
hemorrhage
8 studies included in 
qualitative synthesis
3 studies ischemic stroke
1 study hemorrhagic stroke
4 studies ischemic and 
hemorrhagic stroke (including 
1 AKI-D only)
7 studies included in 
quantitative synthesis (meta-
analysis of proportions)
4 studies mortality
2 studies disability
Fig. 1 PRISMA flow diagram for literature search and study selection
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[19, 25] and higher National Institutes of Health Stroke
Scale (NIHSS) score on admission [20, 25] were all found
to be associated the development of AKI in stroke patients.
Use of angiotensin-converting enzyme inhibitors (ACEi)
and angiotensin II receptor blockers (ARBs) were only mar-
ginally associated with AKI (OR 1.004; 95% CI 0.993–1.058,
P = 0.057) in one study [19]. One study also tested the asso-
ciation between contrast-enhanced computerized tomog-
raphy (CT) and AKI and found no relationship [20].
None of the studies presented data on the adjusted
rates of AKI associated with cerebral angiography,
thrombolysis or any vascular intervention (mechanical
thrombectomy, carotid stenting or endarterectomy).
Two studies [19, 25] examined the relationship between
stroke type and risk of developing AKI after adjustment
for confounders. Covic et al. [19] reported an OR of 2.50
(95% CI 1.42–4.41; P = 0.001) in hemorrhagic stroke and
Tsagalis et al. [25] an OR of 2.02 (95% CI 1.34–3.04; P =
0.001) with lacunar stroke used as the reference.
AKI and severity of stroke
Two studies found an association between stroke severity (as
determined by NIHSS score) and the development of AKI
[20, 25]. In Khatri et al. [20] the adjusted OR per 5 point in-
crease in NIHSS score was 1.13 (95% CI 1.07–1.19; P <
0.001). Tsagalis et al. [25] reported an OR of 1.02 (95% CI
1.01–1.03; P= 0.020) after adjustment for age, sex, presence
of atrial fibrillation (AF), serum glucose, hematocrit and anti-
hypertensive agent use in the first 48 hours of admission.
AKI and degree of disability
Five studies reported disability post stroke with varying defi-
nitions. Two studies [21, 22] recorded degree of disability
post stroke, as measured by the modified Rankin Scale
(mRS). However data from Lin et al. [21] could not be ana-
lyzed with respect to AKI. Mohamed et al. [22] found no as-
sociation between AKI and degree of disability after multiple
adjustments. Two studies [23, 24] used coded discharge des-
tination from NIS data as a surrogate marker for disability.
Discharge was categorized as none to minimal disability and
any other discharge status (home health care, short-term
hospital or other facility including intermediate care and
skilled nursing home or death) as moderate to severe disabil-
ity. Both studies found a higher incidence of moderate to se-
vere disability in patients with AKI after adjustment for
multiple confounders (Saeed et al. 2014, OR 1.3 (95% CI
Table 1 Characteristics of the 8 included studies
Author Type of study/ country No. of
subjects
Age (years) (SD) Men
(%)
Ischemic stroke cases
(%)
AKI
definition
CKD
excluded?
NOS
score
Covic et al.,
2008 [19]
Observational, retrospective,
Romania
1090 66.1 ± 11.5 49.3 932 (85.5%) Creatinine
values;
RIFLE
No 7
(3, 2, 2)
Khatri et al.,
2014 [20]
Observational, retrospective,
United States
1357 64 ± 16 56.0 528 (38.9%) Creatinine
values;
AKIN
GFR
< 15 ml/min
excluded
6
(2, 2, 2)
Lin et al.,
2011 [21]
Observational, prospective, China 2683 66.1 ± 13.59 (AF),
63.58 ± 13.64
(no AF)
58.4 2683 (100%) ICD-10
coding
No 7
(3, 2, 2)
Mohamed
et al.,
2015 [22]
Observational, retrospective,
United States
897 64.4 ± 14.7 44.0 897 (100%) ICD-9
coding
No 7
(3, 2, 2)
Saeed et al.,
2014 [23]
Observational, retrospective, United
States (Nationwide Inpatient
Sample data)
7,068,334 No AKI 71 ± 31,
AKI 74 ± 28
46.1 7,068,334 (100%) ICD-9
coding
Yes 7
(3, 2, 2)
Saeed et al.,
2015 [24]
Observational, retrospective, United
States (Nationwide Inpatient
Sample data)
614,454 No AKI 69 ± 37,
AKI 68 ± 34
52.2 0 (0%) (all cases were
hemorrhagic stroke)
ICD-9
coding
Yes 7
(3, 2, 2)
Tsagalis
et al.,
2008 [25]
Observational, prospective, Greece 2155 70.3 ± 11.9 61.2 1832 (85%) Creatinine
values;
AKIN
No 8
(4, 2, 2)
Nadkarni
et al.,
2015 [26]
Observational, retrospective, United
States (Nationwide Inpatient
Sample data)
4,634,682 AIS
No AKI 73 ± 0.2,
AKI 66 ± 0.3
ICH
No AKI
69.7 ± 0.13,
AKI 65.4 ± 0.21
AIS
50.0
ICH
60.0
3,937,928 (85%) ICD-9
coding
AKI-D only
No 7
(3, 2, 2)
Abbreviations: AIS, acute ischemic stroke; AKI, acute kidney injury; AKI-D, acute kidney injury requiring dialysis; AKIN, Acute Kidney Injury Network; CKD, chronic
kidney disease; GFR, estimated glomerular filtration rate; ICD-9/ 10, International Classification of Diseases, 9th/ 10th Revision; ICH, intracranial hemorrhage; mls/
min, milliliters per minute; NOS, Newcastle-Ottawa Scale; RIFLE, Risk, Injury, Failure, Loss, End-Stage Renal Disease
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1.3–1.4, P < 0.0001); Saeed et al. 2015, OR 1.2 (95% CI 1.1–
1.3, P < 0.0001)). A further study [26] utilized an ‘adverse
discharge’ category to classify patients as being discharged
to a nursing care facility, hospice or long-term care hospital.
Here AKI-D was associated with increased odds of adverse
discharge (adjusted OR 1.18, 95% CI 1.02–1.37, P < 0.01 for
Table 2 Incidence of AKI, associated factors, measured outcomes and adjustments in the 8 included studies
Study Follow
up
Factors associated
with AKI
Crude
Mortality
in AKI
AKI an independent risk factor
for mortality
Disability and AKI LOS (days)
and AKI
Cost and
AKI
Covic et al.,
2008 [19]
30 days Age, renal function
on admission, IHD,
CHF, hemorrhagic
stroke
43.1% vs
12.8%
(P = 0.001)
No Not reported Not reported Not
reported
Khatri et al.,
2014 [20]
Hospital
discharge
Admission
creatinine, NIHSS
score
AIS: 33% vs
10%
(P≤ 0.001)
ICH: 40% vs
30%
(P = 0.020)
For AIS only
OR 3.08 (95% CI 1.49–6.35, P = 0.002)
Adjusted for age, sex, race,
comorbidities, smoking, CTA,
creatinine, NIHSS score
Not reported Unadjusted
AIS: 17.6 vs
8.4 days
(P ≤ 0.001)
ICH: 13.0 vs
8.0 days
(P ≤ 0.001)
Not
reported
Lin et al.,
2011 [21]
1 year Not reported Not
reported
Not reported Not reported Not reported Not
reported
Mohamed
et al.,
2015 [22]
Hospital
discharge
Not reported Not
reported
Not reported Not significant after
adjustment
OR 2.63, 95%
CI 1.51–4.58
Adjusted for
comorbidities,
complications,
NIHSS score
Not
reported
Saeed
et al.,
2014 [23]
Hospital
discharge
Not reported 8.4% vs 2.9%
(P≤ 0.001)
OR 2.2 (95% CI 2.0–2.2, P ≤ 0.001)
Adjusted for age, sex, race,
comorbidities, GI bleeding, sepsis,
nicotine dependence
OR for moderate/
severe disability
1.3 (95% CI 1.3–
1.4, P ≤ 0.001)
Adjusted as for
mortality
Unadjusted 6
vs 4 days
(P < 0.0001)
Unadjusted
USD 38,613
vs 24,474
(P < 0.0001)
Saeed
et al.,
2015 [24]
Hospital
discharge
Not performed AKI: 28.7% vs
22.4%
(P≤ 0.001)
AKI-D vs AKI:
50.2% vs
28.4%
(P≤ 0.001)
OR 1.5 (95% CI 1.4–1.6, P ≤ 0.001)
Adjusted for age, sex, race,
comorbidities, nicotine dependence,
alcohol abuse, hospital bed size,
hospital teaching status
OR for moderate/
severe disability
1.2 (95% CI 1.1–
1.3, P ≤ 0.001)
Adjusted as for
mortality
Unadjusted
12 vs 7 days
(P < 0.0001)
Unadjusted
USD
104,142 vs
54,315
(P < 0.0001)
Tsagalis
et al.,
2008 [25]
10 years NIHSS score, CHF,
ICH, GFR
30-day
mortality
21.8% vs
12.5%
(P = 0.001)
10-year
mortality
75.9% vs
57.7%
(P = 0.001)
10-year HR 1.24 (95% CI 1.07–1.44,
P≤ 0.01),
Adjusted for sex, SBP, hematocrit,
comorbidities, brain edema,
antihypertensives, statin use
Not reported Not reported Not
reported
Nadkarni
et al.,
2015 [26]
AKI-D only
Hospital
discharge
Not performed AIS: 31.8% vs
5.6%
(P≤ 0.01)
ICH: 40.4%
vs 28.5%
(P≤ 0.01)
AIS: OR 1.30
(95% CI 1.02–1.48, P ≤ 0.001)
ICH: OR 1.95
(95% CI 1.61–2.36, P ≤ 0.01)
Adjusted for demographics,
hospital characteristics, Charlson
comorbidity index and other diagnoses
OR for adverse
discharge
category
AIS: 1.18, 95% CI
1.02–1.37, P ≤ 0.01
ICH: 1.74; 95%
CI 1.34–2.24,
P ≤ 0.01
Adjusted as
for mortality
Unadjusted
AIS: 14.1 vs
3.6 days
(P ≤ 0.01)
ICH: 23.5 vs
5.3 days
(P ≤ 0.01)
Unadjusted
AIS: USD
32,596 vs
8039
(P ≤ 0.01)
ICH: USD
58,111 vs
11,255
(P ≤ 0.01)
Abbreviations: AF, atrial fibrillation; AIS, acute ischemic stroke; AKI, acute kidney injury; AKI-D, acute kidney injury requring dialysis; CHD, coronary heart disease;
CHF, congestive heart failure; CT, computerized tomography; CTA, computerized tomography angiography; GFR, glomerular filtration rate; GI, gastrointestinal; ICH,
intracranial hemorrhage; IHD, ischemic heart disease; LOS, length of stay; MI, myocardial infarction, mRS, modified Rankin Scale; NIHSS, National Institutes of
Health Stroke Scale; OR, Odds Ratio; RIFLE, Risk, Injury, Failure, Loss, End-Stage Renal Disease; SBP, systolic blood pressure; TIA, transient ischemic attack; USD,
United States Dollars
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ischemic stroke, adjusted OR 1.74; 95% CI, 1.34–2.24; P <
0.01 for ICH) after adjusting for baseline demographics,
hospital-level characteristics, Charlson comorbidity index
and concurrent diagnoses.
AKI and length of hospital stay and hospitalization costs
Five studies collected data on length of stay (LOS) [20, 22–24,
26]. All studies reported that AKI was associated with an in-
creased length of stay ranging from 2 to 18 extra days spent
in hospital (Table 2). In Mohamed et al. [22], this finding per-
sisted after adjustment for age, NIHSS score, previous stroke
and insurance status (no OR given, adjusted P < 0.0001).
Three studies analyzed crude inpatient costs using NIS
data [23, 24, 26] and all showed AKI was associated with
increased inpatients costs ranging from 14,139 to 49,827
US Dollars (Table 2).
AKI and cardiovascular events
One study [25] examined the relationship between AKI
after a stroke and long-term cardiovascular events. The
probability of having a composite cardiovascular event
during the 10-year period was higher in the AKI group
than the non-AKI group (cumulative probability 66.8
(95% CI 56.6–76.9) vs 52.7 (95% CI 48.5–56.1); P = 0.001).
In a Cox multivariable regression, AKI was an independ-
ent predictor of new composite cardiovascular events at
10 years (hazard ratio 1.22; 95% CI 1.01–1.48, P < 0.05)
after adjustment for hypertension, diabetes, stroke sub-
types, brain edema on imaging and hematocrit.
AKI and post-thrombolytic ICH
Saeed et al. 2014 [23] found that patients with AKI were
more likely to suffer a post-thrombolytic ICH (OR 1.4;
95% CI 1.3–1.6, P < 0.001) after multiple adjustments in-
cluding age, sex, race/ ethnicity, hypertension, diabetes,
AF, dyslipidemia, congestive heart failure, chronic lung
disease, myocardial infarction, gastrointestinal bleeding,
sepsis and nicotine dependence.
AKI and mortality
Six studies [19, 20, 23–26] compared mortality in AKI versus
non-AKI groups with all reporting increased mortality in pa-
tients who developed AKI. Two studies reported higher
crude mortality rates associated with severity of AKI [19, 20].
Four studies reported in-hospital mortality [20, 23, 24,
26] and two reported 30-day mortality [19, 25]. The OR for
all-cause in-hospital mortality in patients with AKI was
2.11 (95% CI 1.09–4.07) with high heterogeneity (I2 100%;
Fig. 3). Excluding Saeed et al. 2015, a study of ICH only, the
OR increased to 2.67 (95% CI 1.86–3.83) and heterogeneity
decreased but remained high (I2 84%). The OR for all-cause
30-day mortality in patients with AKI was 3.13 (95% CI
1.20–8.19), again with high heterogeneity (I2 95%; Fig. 3).
Studies using creatinine values
Studies using coding
14.5
26.68
0.82
17.91
5.27
7.92
6.79
9.61
P
oo
le
d 
A
K
I i
nc
id
en
ce
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at
e 
(%
) 
(9
5%
 C
I)
Fig. 2 Pooled incidence rates of AKI in all studies listed by year. Data labels are percentages with 95% CI. AKI, acute kidney injury; 95%
CI, 95% confidence interval
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Two studies [20, 23] provided data on in-hospital mor-
tality after ischemic stroke with a pooled OR of 3.30
(95% CI 2.56–4.26) and low heterogeneity (I2 31%; Fig. 4).
Two studies [20, 24] provided data on in-hospital mor-
tality after ICH with a pooled OR of 1.40 (95% CI 1.37–
1.43) and low heterogeneity (I2 0%; Fig. 4).
Nadkarni et al. reported an adjusted OR for in-hospital
mortality in AKI-D of 1.30 (95% CI 1.12–1.48; P < 0.001) in
ischemic stroke and 1.95 (95% CI 1.61–2.36; P < 0.01) in
ICH [26]. Since this study included AKI-D only it was ex-
cluded from the meta-analysis. Saeed et al. 2015 reported a
higher crude mortality rate in patients with AKI-D than AKI
without dialysis (50.2% vs 28.4%, P < 0.001) [24].
Only one study provided long-term mortality data up to
10 years [25], demonstrating higher cumulative mortality
in the AKI group at one year (34.6 vs 22.1 in non-AKI
group) and 10 years (75.9 vs 57.7; P = 0.001). In a Cox pro-
portional hazards model AKI was an independent pre-
dictor of 10-year mortality (hazard ratio 1.24; 95% CI
1.07–1.44, P < 0.01) after adjustment for confounders in-
cluding sex, hypertension, hypercholesterolemia, smoking,
systolic blood pressure, brain edema, hematocrit, antihy-
pertensive agent use after the event and ACEi/ARB and
statin use on follow-up. The probability of 10-year mortal-
ity also increased with severity of AKI.
Discussion
We have shown that reported rates of AKI after stroke vary
widely with a range of 0.82% to 26.68%. Increased severity of
stroke is related to the risk of AKI. Furthermore, having an
episode of AKI after a stroke is associated with worse
disability, increased inpatient mortality, LOS and cost, in-
creased risk of future cardiovascular events and longer-term
mortality.
There are marked differences in the reported incidence
rates depending on the methodology used to identify patients
with AKI. Using coding definitions, the pooled incidence of
AKI was 4.63%, compared with 19.51% for definitions based
on serum creatinine values. ICD coding is known to under-
estimate the incidence of AKI [29, 30]. Validation of ICD-9
codes for acute renal failure (ARF, which predates present
use of the term AKI), used in Saeed et al. 2014 and 2015 are
reported to have a sensitivity of 35.4% and a specificity of
97.7%. Thus the low sensitivity for ARF codes may fail to
identify patients with mild AKI that is more likely to go
unrecognized and uncoded [30]. We know that severe AKI
influences a number of outcomes, at high cost to individual
patients, the health service and society [14, 31, 32]. Given that
milder categories of AKI are much more common they may
be even more important to detect and prevent [11, 14, 33].
Furthermore, apart from Nadkarni et al. [26], only one other
study reported data on the incidence of AKI-D and outcomes
[24]. Since more severe AKI is related to worse outcomes,
this is a significant limitation of our meta-analysis. Only three
studies reported on the risk factors associated with AKI after
stroke [19, 20, 25] and generally confined themselves to
reporting on those already known to be associated with AKI.
Only two studies reported that stroke severity at presentation
was associated with an increased risk of AKI [20, 25]. Two
studies reported that hemorrhagic stroke type was associated
with the development of AKI [20, 25]. Interestingly, only one
study [20] investigated the relationship between radiological
contrast exposure and risk of AKI. None of the studies
Fig. 3 AKI and In-Hospital and 30-Day Mortality for all Stroke. AKI, acute kidney injury; 95% CI, 95% confidence interval
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presented data on the association between thrombolysis,
angiographic procedures or vascular intervention in ischemic
stroke and AKI. In light of rapid advances in diagnostic scans
and interventional treatments for stroke in recent years, in-
cluding the use of intra-arterial thrombectomy [3], the inci-
dence of AKI in stroke patients may well increase as these
interventions become more widespread [3].
Lower baseline renal function was associated with an in-
creased rate of AKI in three of the studies in this systematic
review [19, 20, 25]. Patients with CKD are known to have
poorer outcomes after a stroke [34–36]. This leads to the
question of whether AKI adds further clinical relevance to
what is already known about CKD and stroke. Of the stud-
ies that excluded patients with CKD [23, 24], AKI was still
a clinically significant determinant of both disability and
in-hospital mortality after adjustment for multiple con-
founding factors. Two further studies found AKI was still
associated with worse outcomes after adjustment for base-
line renal function or CKD category [20, 25]. This supports
the theory that AKI is not merely an extension of the CKD
spectrum and represents an important standalone factor
that predicts worse outcomes in patients with acute stroke.
Our systematic review demonstrates a clear association be-
tween AKI and short-term mortality after stroke. This effect
persisted after adjustment for CKD in three studies [19, 22,
26]. A further study [25] also found a relationship between
AKI and long-term mortality, up to 10 years post stroke,
after adjustment for CKD and post-stroke pharmaco-
logical treatments. This is consistent with the effect of AKI
on short and long-term mortality in the context of other
acute illnesses including myocardial infarction, sepsis and
major surgery [37–41]. It is therefore, possible that interven-
tions to prevent AKI may improve outcomes after stroke.
Our study has several strengths in that it encompassed
several studies, all within the last decade with a large cu-
mulative sample size and a large number of statistical ad-
justments. However, there are several significant
limitations. Firstly, there was disproportionate representa-
tion of US data, accounting for 99.9% of the patient sam-
ple, which clearly affects generalizability of the estimates.
There may also be significant ascertainment bias in view
of the US being a high income country with increased
availability of blood test monitoring and other diagnostic
tests. Secondly, the number of studies included in the sys-
tematic review was small and those included in the
meta-analysis smaller still. Despite sensitivity analyses,
heterogeneity between studies remained substantial po-
tentially suggesting that these studies should not be com-
bined in a meta-analysis. However, we opted to present
the data, warts and all, as this both highlights the need for
further research in this area but also gives potential future
researchers some idea of the numbers needed for recruit-
ment into studies, as well as the rate and range of AKI to
be expected using different definitions.
Conclusions
AKI appears to be a very common complication in hospi-
talized stroke patients and is associated with increased
mortality, disability and healthcare costs. As a potentially
preventable condition, further studies are needed in this
area to attenuate the effects of AKI, including longer-term
morbidity and mortality and the development of CKD.
However in the first instance, additional representative
studies, ideally using creatinine-based definitions of AKI
are required to accurately determine point estimates of
AKI post stroke and both short and long-term outcomes.
Fig. 4 AKI and In-Hospital Mortality for Ischemic and Hemorrhagic Stroke. AKI, acute kidney injury; 95% CI, 95% confidence interval
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